Integration of gene expression and tumor infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and Nivolumab for patients with Luminal B-like breast cancer in the phase II GIADA trial.
Nivolumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Integration of gene expression and tumor infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and Nivolumab for patients with Luminal B-like breast cancer in the phase II GIADA trial. ### Output: Nivolumab